Literature DB >> 31428952

Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Mohamad Bassam Sonbol1, Thorvardur R Halfdanarson2.   

Abstract

OPINION STATEMENT: In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.

Entities:  

Keywords:  High-grade; Neuroendocrine carcinoma; Neuroendocrine neoplasm; Neuroendocrine tumor; PRRT

Mesh：

Year:  2019        PMID： 31428952     DOI： 10.1007/s11864-019-0670-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  59 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

3.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Authors:  Matthew H Kulke; Keith Stuart; Peter C Enzinger; David P Ryan; Jeffrey W Clark; Alona Muzikansky; Michele Vincitore; Ann Michelini; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

4.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

5.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan R Strosberg; Robert L Fine; Junsung Choi; Aejaz Nasir; Domenico Coppola; Dung-Tsa Chen; James Helm; Larry Kvols
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

7.  ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis.

Authors:  G Rindi; C Azzoni; S La Rosa; C Klersy; D Paolotti; S Rappel; M Stolte; C Capella; C Bordi; E Solcia
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

Review 8.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features.

Authors:  Antongiulio Faggiano; Jean-Cristophe Sabourin; Michel Ducreux; Jean Lumbroso; Pierre Duvillard; Sophie Leboulleux; Clarisse Dromain; Annamaria Colao; Martin Schlumberger; Eric Baudin
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

10.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544
View more
  4 in total

1.  Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.

Authors:  Alex J Liu; Benjamin E Ueberroth; Patrick W McGarrah; Skye A Buckner Petty; Ayse Tuba Kendi; Jason Starr; Timothy J Hobday; Thorvardur R Halfdanarson; Mohamad Bassam Sonbol
Journal:  Oncologist       Date:  2021-02-08

Review 2.  Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.

Authors:  Gabriel Benyomo Mpilla; Philip Agop Philip; Bassel El-Rayes; Asfar Sohail Azmi
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

Review 3.  Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

4.  Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.

Authors:  Mojun Zhu; Mohamad Bassam Sonbol; Thorvardur Halfdanarson; Timothy Hobday; Daniel Ahn; Wen Wee Ma; Tanios Bekaii-Saab
Journal:  Oncologist       Date:  2020-07-01       Impact factor: 5.837
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.